title: Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
abstract: Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.
authors.affiliation: Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, USA. asher.chanan-khan@roswellpark.org
authors.forename: Asher A
authors.initials: AA
authors.lastname: Chanan-Khan
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Kaufman
authors.forename: Jayesh
authors.initials: J
authors.lastname: Mehta
authors.forename: Paul G
authors.initials: PG
authors.lastname: Richardson
authors.forename: Kena C
authors.initials: KC
authors.lastname: Miller
authors.forename: Sagar
authors.initials: S
authors.lastname: Lonial
authors.forename: Nikhil C
authors.initials: NC
authors.lastname: Munshi
authors.forename: Robert
authors.initials: R
authors.lastname: Schlossman
authors.forename: Joseph
authors.initials: J
authors.lastname: Tariman
authors.forename: Seema
authors.initials: S
authors.lastname: Singhal
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D011719:Pyrazines / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000150:complications / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D012189:Retrospective Studies
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib